Skip to main content
AKTX
NASDAQ Life Sciences

Akari Therapeutics Completes Final Tranches of Highly Dilutive Private Placement

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$9.32
Mkt Cap
$10.896M
52W Low
$3.015
52W High
$49.6
52W Position info
209% above low
Off High info
81% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

AKTX has more than doubled off its 52-week low of $3.015 on light trading volume (0.1× avg).

Summary

Akari Therapeutics completed the final tranches of a previously announced private placement, issuing 980,395 ADSs for approximately $3.67 million, which is highly dilutive but provides critical funding for the financially distressed company.


Key Events · Financing and Capital Events · AKTX

  • Consolidated Private Placement Closing

    The company combined the second and third tranches of a private placement into a single closing on June 26, 2026, accelerating the funding timeline.

  • Issuance of ADSs

    980,395 American Depository Shares (or prefunded warrants in lieu thereof) were issued and sold to investors.

  • Significant Capital Infusion

    This issuance represents approximately $3.67 million in gross proceeds, providing critical funding for the company which previously reported a cash runway only into June 2026.

  • High Dilution

    The capital raise is highly dilutive, representing over 30% of the company's current market capitalization, and was priced at a deep discount to market.


Analysis · AKTX · Life Sciences

This filing confirms the closing of a significant portion of a previously announced dilutive private placement. The company, facing a "going concern" warning and limited cash runway, has secured critical funding by issuing 980,395 ADSs for approximately $3.67 million at a deep discount. This provides a short-term lifeline but at a substantial cost to existing shareholders through significant dilution. Further dilution from associated warrants is pending shareholder approval on June 30.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 44.9% of the 1407 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, AKTX was trading at $9.32 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.9M. The 52-week trading range was $3.02 to $49.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AKTX - Latest Insights

AKTX
Aug 18, 2026, 8:56 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $7.79
Real-time Price: $7.75 info
Change: -$0.040 (-0.51%) info
Market Cap: $16.261M info
AKTX
Aug 13, 2026, 4:02 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $7.00
Real-time Price: $7.75 info
Change: +$0.750 (+11%) info
Market Cap: $16.261M info
AKTX
Aug 13, 2026, 4:00 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $7.00
Real-time Price: $7.75 info
Change: +$0.750 (+11%) info
Market Cap: $16.261M info
AKTX
Jul 08, 2026, 4:15 PM EDT
Filing Type: S-3/A
Importance Score:
9
Price at Filing: $14.21
Real-time Price: $7.75 info
Change: -$6.46 (-45%) info
Market Cap: $16.261M info
AKTX
Jul 02, 2026, 5:25 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $10.41
Real-time Price: $7.75 info
Change: -$2.66 (-26%) info
Market Cap: $16.261M info